Anti-digoxin polyclonal antibody

Drug Profile

Anti-digoxin polyclonal antibody

Alternative Names: DIF; DigiBind; DigiFab; Digoxin Immune Fab; Digoxin Immune Fab (Ovine); Polyclonal antibody DigiTAb

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Glenveigh Pharmaceuticals; Protherics
  • Developer BTG; Glenveigh Pharmaceuticals
  • Class Antidotes; Polyclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Preeclampsia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Preeclampsia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Poisoning
  • Phase II Preeclampsia

Most Recent Events

  • 29 Dec 2016 Velo Bio plans a phase II trial for Preeclampsia in USA (IV, Infusion) (NCT03008616)
  • 29 Jul 2015 AMAG Pharmaceuticals has patent protection for anti-digoxin polyclonal antibody
  • 29 Jul 2015 Velo Bio plans a IIb/IIIa trial and a dose ranging study preeclampsia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top